2 March 2018 - The utilisation analysis public release documents from the September 2017 DUSC meeting are now available.

DUSC considered the following:

• 5-aminosalicylic acids for ulcerative colitis
  
• Eculizumab for aHUS
  
• Everolimus and sunitinib for pNET
  
• Lenalidomide for myelodysplastic syndrome
  
• Nab-paclitaxel for pancreatic cancer
  
• Multiple myeloma
  

Read DUSC public release document